truvada is just tenofovir+ftc, it is sueless on hbv unless non response to tenofovir, which is extremely rare
it adds toxicity and higher price because truvada patent is not expiring in 2014, no difference on hbsag.
instead of truvada it is best only for those non responding to combo tenofovir+lamivudine.
I was also a reciever. After 40 hours I went to the first clinic and they gave me PEP (TenofovirDF, emtricitabine + lamivudine). The clinic looks very unprofessional, but it was my only chance. I didn't do any hiv or std test, a month before the exposure i had HIV test which was negative. After few days I had a mild sore throat, i still have it, i don't have fever, running nose, rash or anything else. My questions are..
An international study found the antiviral combination of tenofovir and emtricitabine (Truvada) was most effective in treating younger adult hepatitis B patients with high viral load and normal ALT levels.
Doctors historically have not treated this group because there appeared to be no sign of liver damage. However, doctors now know that high viral loads may increase patients’ risk of liver damage and cancer as they age, despite their normal ALT levels.
What are my chances of getting infected. Another question was administered a PEP drug emtricitabine and tenofovir, can it prevent me from contracting HiV.
Tenofovir alafenamide (TAF), a new formulation that reaches higher levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation but had less impact on markers of kidney function and bone turnover, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.
You are correct that Truvada is a combination of tenofovir and emtricitabine, and is generally prescribed for patients with HIV. Being a HBV forum, most of us know very little about Truvada except that it is prescribed off-label for HBV by some doctors, and that it is recommended for HBV patients who develop resistance to Tenofovir.
Yes, a PFO can cause fatigue as the blood/oxygen level pumped into circulation may be compromised. More likely, the cause of being tired can be related to low blood sugar and anemia.
FTC is Emtricitabine.
This is a potential concern because the drugs in Truvada – tenofovir and emtricitabine – are active against HBV as well as HIV.
HIV and HBV are spread through some common transmission routes, including sexual transmission, vertical transmission (mother to child) and via multi-person use of injection equipment.
I asked her of her status and she stated clean. I started PEP within 24 hours. (Teneogovir, emtricitabine, lamivudine ) What are the odds of being infected ? is this low risk ?
I started a course of PEP that included Tenvor-EM (Indian version Emtricitabine/Tenofovir DF) and Kaluvia (generic of lopinavir/retonavir) for 25 days and interrupted it for two reasons:
1-My partner tested Negative(Antigen/ Antibody) on 22 days post exposure
2-Thinking that i might be developing facial Lipodystrophy (slight facial fat loss under cheek bones). I cant tell if my face was like this before the treatment or it is just an illusion.
CENTRAL CANAL AND NEURAL FORAMINA ARE WIDELY PATENT. L2-L3 CENTRAL CANAL AND NEURAL FORMINA ARE WIDELY PATENT . L3-L4 CENTRAL CANAL AND NEURAL FORAMINA ARE WIDELY PATENT. MILD FACET HYPERTROPHIC CCHANGES ASND MILD LIGAMENTUM FLAVUM HYPERTROPHIC CHANGES. L4-L5 BROAD BAESD ANNULAR DISC BULGE EFFACES THE ANTERIOR ASPECT OF THE THECAL SAC MIDLY SO. DISC LATERALIZES TO THE RIGHT GREATER THAN LEFT. CORRELATE REGARDING RADICULAR SYMPTOMS.
No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg- Chronic Hepatitis B Virus Infection
P. Marcellin1; E. Heathcote2; A. Corsa3; Y. Liu3; M. D. Miller3; K. M. Kitrinos3
1. Hopital Beaujon, University of Paris, Clichy, France.
2. Toronto General Hospital, Toronto, ON, Canada.
3. Gilead Sciences, Inc., Foster City, CA, United States.
ALNY) disclosed on Thursday the receipt of a US new patent under its McSwiggen patent estate for the advancement of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection.
The company added that the US patent no. 8,618,277, or '277 patent, which includes broad, sequence-independent issued claims on compositions of chemically modified siRNA targeting HBV, was awarded by the US Patent and Trademark Office (USPTO).
Recommended
